Evidence map›Paper›PMID 38611024›Full record

ReviewCancers2024

Risk-Tailoring Radiotherapy for Endometrial Cancer: A Narrative Review.

Kristin Hsieh, Julie R Bloom, Daniel R Dickstein, Anuja Shah, Catherine Yu, Anthony D Nehlsen, Lucas Resende Salgado, Vishal Gupta, Manjeet Chadha, Kunal K Sindhu

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristin HsiehDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4100-473X
Julie R BloomDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Daniel R DicksteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Anuja ShahDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Catherine YuDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-4967-6100
Anthony D NehlsenDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-3210-1415
Lucas Resende SalgadoDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Vishal GuptaDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Manjeet ChadhaDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Kunal K SindhuDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9376-8307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer is the most common gynecologic cancer in the United States and it contributes to the second most gynecologic cancer-related deaths. With upfront surgery, the specific characteristics of both the patient and tumor allow for risk-tailored treatment algorithms including adjuvant radiotherapy and systemic therapy. In this narrative review, we discuss the current radiation treatment paradigm for endometrial cancer with an emphasis on various radiotherapy modalities, techniques, and dosing regimens. We then elaborate on how to tailor radiotherapy treatment courses in combination with other cancer-directed treatments, including chemotherapy and immunotherapy. In conclusion, this review summarizes ongoing research that aims to further individualize radiotherapy regimens for individuals in an attempt to improve patient outcomes.

Indexed as

endometrial cancerpersonalized treatmentradiation-induced toxicitiesradiation oncologyradiotherapyrisk-tailoringuterine malignancy

Identifiers

PMID38611024
PMCPMC11011021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.